Savara Inc Cash and Cash Equivalents
Savara Inc (SVRA) had Cash and Cash Equivalents of $41.80 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-11
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $41.80M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $38.79M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $33.18M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $16.28M.
| Period end | Cash and Cash Equivalents, at Carrying Value | Cash and Cash Equivalents, at Carrying Value as first filed |
|---|---|---|
| 2026-06-30 | $41.80M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | $38.79M 10-Q · filed 2026-05-12 | |
| 2025-12-31 | $33.18M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | $16.28M 10-Q · filed 2025-11-12 | |
| 2025-06-30 | $17.44M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | $19.56M 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $15.13M 10-K · filed 2026-03-13 | |
| 2024-09-30 | $21.43M 10-Q · filed 2024-11-12 | |
| 2024-06-30 | $23.86M 10-Q · filed 2024-08-12 | |
| 2024-03-31 | $16.79M 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $26.59M 10-K · filed 2025-03-27 | |
| 2023-09-30 | $27.69M 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $22.75M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $33.98M 10-Q · filed 2023-05-15 | |
| 2022-12-31 | $52.10M 10-K · filed 2024-03-07 | |
| 2022-09-30 | $119.84M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $95.15M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $79.23M 10-Q · filed 2022-05-11 | |
| 2021-12-31 | $34.01M 10-K · filed 2023-03-30 | |
| 2021-09-30 | $44.70M 10-Q · filed 2021-11-12 | |
| 2021-06-30 | $40.65M 10-Q · filed 2021-08-12 | |
| 2021-03-31 | $55.98M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $22.88M 10-K · filed 2022-03-30 | |
| 2020-09-30 | $35.22M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $47.12M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $34.52M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $49.80M 10-K · filed 2021-03-10 | |
| 2019-09-30 | $17.79M 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $16.83M 10-Q · filed 2019-08-08 | |
| 2019-03-31 | $25.67M 10-Q · filed 2019-05-09 | |
| 2018-12-31 | $24.30M 10-K · filed 2020-03-12 | |
| 2018-09-30 | $24.95M 10-Q · filed 2018-11-07 | |
| 2018-06-30 | $23.60M 10-Q · filed 2018-08-09 | |
| 2018-03-31 | $22.12M 10-Q · filed 2018-05-09 | |
| 2017-12-31 | $22.12M 10-K · filed 2019-03-13 | |
| 2017-09-30 | $19.81M 10-Q · filed 2017-11-08 | |
| 2017-06-30 | $61.13M 10-Q · filed 2018-08-09 | |
| 2017-03-31 | $10.46M 10-Q · filed 2018-05-09 | $7.77M 10-Q · filed 2017-05-09 |
| 2016-12-31 | $13.37M 10-Q · filed 2018-08-09 | $8.54M 10-K · filed 2017-03-06 |
| 2016-09-30 | $15.51M 10-Q · filed 2017-11-08 | $20.52M 10-Q · filed 2016-11-08 |
| 2016-06-30 | $14.06M 10-Q · filed 2017-08-09 | $24.49M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $23.52M 10-Q · filed 2017-05-09 | |
| 2015-12-31 | $16.68M 10-K · filed 2018-03-14 | $23.05M 10-K · filed 2016-03-14 |
| 2015-09-30 | $32.21M 10-Q · filed 2016-11-08 | |
| 2015-06-30 | $21.21M 10-Q · filed 2016-08-09 | |
| 2015-03-31 | $27.93M 10-Q · filed 2016-05-06 | |
| 2014-12-31 | $12.69M 10-K · filed 2018-03-14 | $35.81M 10-K · filed 2015-03-24 |
| 2014-09-30 | $25.98M 10-Q · filed 2015-11-12 | $25.98M 10-Q · filed 2014-10-31 |
| 2014-06-30 | $26.37M 10-Q · filed 2015-08-12 | $26.37M 10-Q · filed 2014-08-11 |
| 2014-03-31 | $29.85M 10-Q · filed 2015-05-11 | $29.85M 10-Q · filed 2014-05-05 |
| 2013-12-31 | $25.68M 10-K · filed 2017-03-06 | $25.68M 10-K · filed 2014-03-26 |
| 2013-09-30 | $30.23M 10-Q · filed 2014-10-31 | |
| 2013-06-30 | $44.97M 10-Q · filed 2014-08-11 | |
| 2013-03-31 | $21.41M 10-Q · filed 2014-05-05 | |
| 2012-12-31 | $22.50M 10-K · filed 2015-03-24 | $22.50M 10-K · filed 2013-03-19 |
| 2012-09-30 | $26.09M 10-Q · filed 2013-11-04 | |
| 2012-06-30 | $29.96M 10-Q · filed 2013-08-05 | |
| 2012-03-31 | $35.05M 10-Q · filed 2013-05-15 | |
| 2011-12-31 | $43.57M 10-K · filed 2014-03-26 | |
| 2011-09-30 | $32.77M 10-Q · filed 2012-11-05 | |
| 2011-06-30 | $41.96M 10-Q · filed 2012-08-06 | |
| 2011-03-31 | $46.55M 10-Q · filed 2012-05-07 | |
| 2010-12-31 | $27.98M 10-K · filed 2013-03-19 | |
| 2010-09-30 | $29.33M 10-Q · filed 2011-11-08 | |
| 2010-06-30 | $31.16M 10-Q · filed 2011-08-08 | |
| 2009-12-31 | $8.67M 10-K · filed 2012-03-08 | |
| 1996-09-12 | $32.77M 10-Q · filed 2011-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |